Sophia Genetics, Memorial Sloan Kettering Ink MOU for Precision Oncology Hub
The two institutions will launch a joint venture combining MSKCC's clinical genomic datasets with Sophia’s AI platform.
Sophia Genetics and Memorial Sloan Kettering Cancer Center have signed a memorandum of understanding to form a joint venture focused on developing and deploying precision oncology tools to patients worldwide.
The proposed hub, announced June 4, would combine MSKCC’s clinical data and scientific expertise with Sophia’s SOPHiA DDM platform, which the company describes as an AI and analytics layer for precision medicine. Under the envisioned structure, SOPHiA DDM would serve as the hub’s AI, data, and bioinformatics backbone, while MSKCC would contribute its oncology faculty, clinical leadership, and capacity to generate high-quality patient data.
Specific terms of the joint venture have not yet been finalized, the partners said in a statement, and financial details were not disclosed.
“This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge Ai and robotics with the potential to transform cancer care at scale,” Michael Frank, Director of Digital Health Business Development at MSKCC, said in a statement:
Both institutions bring substantial genomic datasets to the arrangement. SOPHiA DDM has been used to analyze more than 2.5 million cases since 2014, while MSK’s in-house next-generation sequencing program has sequenced more than 150,000 tumor samples over the same time frame, building a dataset linked to clinical outcomes, pathology, and radiology records.
The deal builds on an existing relationship between the entities. Through prior licensing agreements covering sequencing-based cancer panels including MSK-IMPACT and MSK-ACCESS, Sophia has distributed MSK diagnostic tools in 35 countries.
MSKCC and Sophia suggested that their biopharma partners would gain access to infrastructure for companion diagnostic development, clinical algorithm development, and evidence generation.
No timeline for finalizing the joint venture agreement was disclosed.